Physician profile
Daniel Park
NPI 1124201801
$4,851.05
in general payments reported to CMS, 2019-2025
30 companies · $822 in 2025
The $822 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $413 · 2021: $873 · 2022: $1,092 · 2023: $839 · 2024: $99.92 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,013.86 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $914.88 | 2019-2025 | Ingrezza |
| Abbvie INC. | $821.29 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $386.65 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $305.89 | 2020-2024 | Uzedy |
| Axsome Therapeutics, INC. | $188.80 | 2023-2024 | Auvelity |
| Alkermes, INC. | $181.06 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $144.89 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $136.71 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $105.11 | 2025 | Cobenfy |
| Eisai INC. | $72.59 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.00 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $57.67 | 2019-2025 | Fanapt |
| Lundbeck LLC | $55.10 | 2019-2020 | |
| Shire North American Group INC | $48.15 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $42.60 | 2022-2025 | Qelbree |
| Bausch Health US, LLC | $36.24 | 2022 | |
| Jazz Pharmaceuticals INC. | $35.79 | 2020 | |
| Sage Therapeutics, LLC | $32.98 | 2025 | Zurzuvae |
| Indivior INC. | $31.60 | 2025 | Sublocade |
| Almatica Pharma LLC | $29.38 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Penumbra, INC. | $23.96 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.64 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $19.96 | 2020 | |
| Neuronetics, INC. | $19.26 | 2023 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $15.90 | 2019 | |
| Bioxcel Therapeutics, INC. | $15.15 | 2023 | Igalmi |
| Medtronic USA, INC. | $13.21 | 2019 | |
| Allergan, INC. | $12.02 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.